RGEN Stock Analysis: Buy, Sell, or Hold?
RGEN - Repligen Corp
$103.38
-3.65 (-3.41%)
▼
5d:
-18.23%
30d:
-21.64%
90d:
-22.05%
WAIT
LOW Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 05, 2026
0d
Get Alerted When RGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: RGEN is down 18.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: RGEN is down 18.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$124.29
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$77.17
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RGEN is currently trading at $103.38, which is considered oversold relative to its 30-day fair value range of $113.29 to $128.01. From a valuation perspective, the stock is trading at a discount (Forward PE: 41.9) compared to its historical average (62.1). Remarkably, the market is currently pricing in an annual earnings decline of 12.3% over the next few years. This pessimistic expectation contrasts with the company's recent 47.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, RGEN is in a strong downtrend. The price is currently testing key support at $103.42. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $179.78 (+68.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RGEN is in a strong downtrend. The price is currently testing key support at $103.42. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $179.78 (+68.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$113.29 -
$128.01
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.4%)
- BULLISH: Trading 68.0% below Wall St target ($179.78)
- WARNING: Recommendation downgraded due to -18.2% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$113.29 -
$128.01
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$103.42
Resistance Level
$131.53
Current Trend
Strong Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
41.92
Wall Street Target
$179.78
(+68.0%)
Revenue Growth (YoY)
14.8%
Earnings Growth (YoY)
47.9%
Profit Margin
6.7%
Valuation Discount vs History
-12.3% cheaper
PE vs Historical
41.9 vs 62.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-12.3%
(market-implied from PE analysis)
1-Year Target
$96.33
(-10%)
2-Year Target
$86.69
(-19%)
3-Year Target
$78.02
(-27%)
3-Yr Target (if PE normalizes)
(PE: 42→62)
$115.58
(+8%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 41.9, Growth: 27.6%)
$222.52
(+108%)
Base:
(SPY PE: 22.0, Growth: 27.6%)
$116.98
(+9%)
Bear:
(PE: 18.7, Growth: 27.6%)
$99.44
(-7%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (63x PE), but valuation improves significantly next year (42x PE) as earnings recover.
Forward PE: 62.50 | Forward EPS (Implied): $1.71
Bull Case
$129.24
(+21%)
Analyst growth 15.0%, PE expands to 65.6
Base Case
$107.03
(0%)
Market implied 0.0%, PE stable at 62.5
Bear Case
$81.88
(-24%)
Severe decline -15.0%, PE contracts to 56.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 41.9 to 62.1
Stabilization Target:
$158.54
(+48.1%)
PE Expansion Potential:
+48.1%
Share & Embed Analysis
Last updated: May 14, 2026 4:34 PM ET
Data refreshes hourly during market hours. Next update: 5:34 PM
Data refreshes hourly during market hours. Next update: 5:34 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Karen A Dawes
SELL
275 shares
2025-12-17
James Bylund
SELL
2191 shares
2025-11-18
James Bylund
SELL
2191 shares
2025-11-18
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$577 | 58 HOLD |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$88 | 53 HOLD |
|
RMD
ResMed Inc |
BUY
19 analysts |
$271 | 59 HOLD |
|
COO
The Cooper Companies, Inc |
BUY
19 analysts |
$91 | 64 BUY |
|
WST
West Pharmaceutical Serv… |
STRONG BUY
13 analysts |
$350 | 54 HOLD |
